Welcome, Guest. Please login or register.
March 28, 2024, 02:42:30 am

Login with username, password and session length


Members
  • Total Members: 37612
  • Latest: testABC
Stats
  • Total Posts: 772944
  • Total Topics: 66310
  • Online Today: 161
  • Online Ever: 5484
  • (June 18, 2021, 11:15:29 pm)
Users Online
Users: 3
Guests: 154
Total: 157

Welcome


Welcome to the POZ Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Do I Have HIV?” posting guidelines. Click here for posting guidelines pertaining to all other POZ community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Bioo Scientific and Texas Tech Collaborate to Suppress the Progression of HIV Us  (Read 4085 times)

0 Members and 1 Guest are viewing this topic.

Offline marius68

  • Member
  • Posts: 27
More good news on the gene therapy front!!! The train is, no doubts, unstoppable!! I only hope it happens soon and the small biotech companies/academic research partnerships have the support to make things happen! Again this amazing development is the result of direct investment if R&D.

http://www.biootherapeutics.com/Bioo%20Scientific%20and%20Texas%20Tech%20Collaborate.pdf

http://www.pressreleasepoint.com/bioo-scientific-and-texas-tech-collaborate-suppress-progression-hiv-using-targeted-rnai


Austin, TX – (November 13, 2009) Dr Premlata Shankar, Professor and Co-Director, Center of Excellence of Infectious Disease Research at Texas Tech University, who has developed RNAi-based treatment methods for HIV infection, recently entered into a collaborative research agreement with Bioo Therapeutics, a division of Bioo Scientific, to leverage their T3™ technology to facilitate the targeted delivery of siRNA into T cells. Dr. Shankar has already successfully used RNAi to dramatically suppress HIV infection in mice by knocking down three key genes which prevented the HIV infection from spreading.
Bioo Scientific’s T3 Technology will allow Dr Shankar to precisely target the delivery of siRNAs in vivo into T-cells, although it can be used to target any cell type. The patent pending T3 Technology functions by conjugating an RNAi agent carrier to a monoclonal antibody to produce a conjugate, which is then loaded with an RNAi agent such as siRNA or miRNA molecules. The RNAi agent loaded conjugate is administered to an animal where it binds to and is internalized by cells recognized by the monoclonal antibody. The RNAi agent is then released to reduce the expression of its intended target. T3 technology can propel the validation of animal experimentation, leading to a better understanding of cellular pathways, the identification of novel drug targets, and the ability to more efficiently deliver RNAi agents as drugs.
“I am delighted to join forces with Bioo Scientific in the development of an advanced monoclonal antibody based technology for targeted delivery of siRNA to T cells and potentially other cell types” Dr. Shankar said. “By combining our scientific expertise and resources, we can speed up the development of robust enabling platforms for efficient delivery to desired cells and tissues in vivo which is critical for translating siRNAs into a novel class of drugs to treat human diseases.”
About Bioo Therapeutics
Bioo Therapeutics is a division of Bioo Scientific, is an Austin, TX based biotechnology company that provides innovative solutions to the life science industry. Bioo Therapeutics was launched to leverage Bioo Scientific’s proprietary drug delivery vehicles and extensive experience in antibody and small molecule research to use as a basis to develop therapeutic agents to combat cancer and other diseases. For more information about Bioo Therapeutics, visit www.biootherapeutics.com.

Offline Inchlingblue

  • Member
  • Posts: 3,117
  • Chad Ochocinco PETA Ad
This is very promising. Below is a link to an article describing a different experiment using siRNA on mice that have an immune system which mirrors a human one.

The team injected the mice with human blood stem cells, which divided time and again, building a human immune system in their hosts. When infected with HIV, the synthetic immune system seemed to respond as it would in humans, since T cell levels followed the same pattern in both species.

Kumar's siRNAs halted T cell destruction in the mice, essentially stopping the virus in its tracks.
"Both prophylactic and therapeutic regimens proved successful," said Kumar. "Apparently, the siRNAs kept HIV from entering most T cells and kept it from replicating when it managed to slip inside."


LINK:

http://www.sciencedaily.com/releases/2008/08/080807130828.htm

Offline marius68

  • Member
  • Posts: 27
No doubts the future of HIV (also cancer) treatment/cure is with gene therapy or other biochemical approaches.  Small molecule drugs, can be improved but will be more of the same. Small molecule drugs are very non-specific and will always have serious side-effects. One application of this kind of drugs is activation of the reservoirs. But that is, hopefully, a on/off application. The problem is how to guarantee that the new therapies progress through the small biochem's pipelines. The business of traditional big pharma is in small molecule drugs and will be very difficult to change. It's something new for them. Partnerships between the public and provide sectors are necessary to advance all these promising therapies.

 


Terms of Membership for these forums
 

© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.